早期吗啡给药对先前存在慢性心力衰竭的败血症患者的影响
1Department of Critical Care Medicine, Shenzhen Second People's Hospital & First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Clinics (Sao Paulo, Brazil)
|April 25, 2025
概括
在患有慢性心力衰竭 (CHF) 的败血症患者中,早期使用吗啡与更好的生存率有关. 这项研究发现,在败血症期间接受早期吗啡的CHF患者中,30天死亡率降低.
科学领域:
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于长期心力衰竭 (CHF) 的败血症患者使用吗啡的数据有限.
- 吗啡给药对这种人群中败血症存活率的影响尚不清楚.
研究的目的:
- 调查早期吗啡给药和30天死亡率之间的关联,在有史以来心血管不全的败血症患者中.
主要方法:
- 使用MIMIC-IV数据库进行回顾性队列研究.
- 分析了7424名患有心血管不全的成人败血症患者.
- 雇员考克斯比例危险建模和倾向性得分匹配 (PSM).
主要成果:
- 早期服用吗啡与显著降低30天死亡率有关 (16.4%对比25.7%后匹配).
- 在调整后的变量中观察到30天死亡率降低 (HR = 0.5390.735,p < 0.001).
- 15毫克以下的吗啡剂量与PSM后较低的死亡率相关 (HR = 0.233,p < 0.001).
结论:
- 早期服用吗啡与慢性心血管疾病的败血症患者的风险调整后30天死亡率降低显著相关.
相关概念视频
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
Opioid Analgesics: Synthetic and Semisynthetic Opioids
172
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
172


